801 Risk-benefit ratio in immunotherapy (IO) with or without chemotherapy (CT) according to PD-L1 expression: a model-based approach to inform treatment decisions in metastatic non-small cell lung cancer

• Ting Chen,
• Ana Ruiz,
• Molly Zhao,
• Naveen Mangal,
• Matthew L Zierhut,
• Han Witjes,
• Thao Dang,
• Sandhya Girish,
• Sreeneeranj Kasichayanula

Affiliations

Ting Chen

1Gilead Sciences, Inc., Foster City, CA, USA

Ana Ruiz

1Gilead Sciences, Inc., Foster City, CA, USA

Molly Zhao

1Gilead Sciences, Inc., Foster City, CA, USA

Naveen Mangal

1Gilead Sciences, Inc., Foster City, CA, USA

Matthew L Zierhut

2Certara USA, Inc., Princeton, NJ, USA

Han Witjes

2Certara USA, Inc., Princeton, NJ, USA

Thao Dang

1Gilead Sciences, Inc., Foster City, CA, USA

Sandhya Girish

1Gilead Sciences, Inc., Foster City, CA, USA

Sreeneeranj Kasichayanula

1Gilead Sciences, Inc., Foster City, CA, USA